)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Galecto (GLTO) investor relations material
Galecto Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary5 Aug, 2025
Executive summary
Focus shifted to oncology and severe liver diseases, prioritizing GB3226 and GB1211 after a strategic review and asset acquisition from Bridge Medicines in October 2024.
GB3226, a dual ENL-YEATS and FLT3 inhibitor for AML, is advancing toward IND submission in Q1 2026, with initial clinical data expected in 2027.
Preclinical data show GB3226 efficacy as monotherapy and in combination, outperforming current FLT3 and menin inhibitors.
GB1211 continues in an investigator-initiated Phase 2 trial for metastatic melanoma and HNSCC, with promising early results in combination with checkpoint inhibitors.
Substantial additional capital will be required to advance clinical programs and maintain operations.
Financial highlights
Net loss for Q2 2025 was $3.4 million, or $(2.60) per share, improved from $5.3 million, or $(4.92) per share, year-over-year.
Operating expenses for Q2 2025 decreased 39% year-over-year to $3.4 million, reflecting lower R&D and G&A costs.
Research and development expenses for the quarter fell to $1.5 million from $1.8 million year-over-year, mainly due to reduced personnel and consulting costs.
General and administrative expenses for Q2 2025 were $2.0 million, down from $2.8 million in Q2 2024, driven by lower personnel and legal costs.
No restructuring costs in 2025; prior year included $1.0 million in such expenses.
Outlook and guidance
Existing cash of $10.2 million as of June 30, 2025, is expected to fund preclinical development and IND submission for GB3226 into 2026.
Additional funding is required for clinical development and to continue as a going concern beyond the next 12 months.
If unable to secure funding, may need to reduce spending, delay or eliminate programs, or consider liquidation.
What is the Q2 2025 cash burn rate?
What specific CMC costs increased in Q2 2025?
What specific patient genotypes does GB3226 target?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Galecto earnings date
Q3 20254 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Galecto Inc. is a clinical-stage biotechnology company primarily focused on the development of small molecule therapeutics aimed at critical aspects of cancer and fibrotic diseases. Their research and development efforts are centered around the inhibition of galectin-3 and lysyl oxidase-like 2 (LOXL2), proteins that play a pivotal role in the progression of these conditions. Galecto's portfolio includes GB0139, designed for treating Idiopathic Pulmonary Fibrosis (IPF), a serious progressive fibrotic lung disease; GB1211, a selective oral small molecule inhibitor of galectin-3 for various oncology indications and liver cirrhosis; and GB2064, targeting LOXL2 for the treatment of myelofibrosis. The company is headquartered in Boston, Massachusetts, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage